The Value of Proof-Of-Concept
Big Pharma's unprecedented spending levels in licensing continue. But some recent deals suggest the real linchpin of licensing value is proof-of-concept in humans.
Big Pharma's unprecedented spending levels in licensing continue. But some recent deals suggest the real linchpin of licensing value is proof-of-concept in humans.